Update on Adolescent Immunization: Review of Pertussis and the Efficacy, Safety, and Clinical Use of Vaccines That Contain Tetanus-Diphtheria-Acellular Pertussis

Journal of Pediatric Health Care

Volumn 20, Issue 4, 2006, Pages 229-237

  Wilson, Thad R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; PERTUSSIS VACCINE;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CHILD HEALTH CARE; DISEASE PREDISPOSITION; HEALTH SURVEY; HUMAN; IMMUNIZATION; IMMUNOLOGY; INCIDENCE; METHODOLOGY; NURSE PRACTITIONER; PERTUSSIS; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; RISK FACTOR; SAFETY; STATISTICS; UNITED STATES; VACCINATION;

ADOLESCENT; ADOLESCENT HEALTH SERVICES; AGE DISTRIBUTION; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DISEASE SUSCEPTIBILITY; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INCIDENCE; NURSE PRACTITIONERS; PERTUSSIS VACCINE; POPULATION SURVEILLANCE; PRACTICE GUIDELINES; PRIMARY HEALTH CARE; RISK FACTORS; SAFETY; UNITED STATES; VACCINATION; WHOOPING COUGH;

EID: 33745685547     PISSN: 08915245     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pedhc.2005.12.011     Document Type: Article

References (61)

1. ADACEL. (2005). Prescribing information. Aventis Pasteur Limited, Toronto, Ontario, Canada.
2. Advisory Committee on Immunization Practices. (June 30, 2005). ACIP recommends adolescent vaccination for tetanus, diphtheria and pertussis vaccine [National Immunization Program press release]. Retrieved July 25, 2005 from http://www.cdc.gov/nip/pr/pr_tdap_jun2005.htm
3. American Medical Association. AMA guidelines for adolescent preventive services (GAPS). Recommendations and rationale (1997), Department of Adolescent Health, American Medical Association, Chicago
4. Aoyama T., Arracima M., Nishimura K., and Saito Y. Outbreak of pertussis in highly immunized adolescents and its secondary spread to their families. Acta Paediatrica, Japonica 37 (1995) 321-324
5. BOOSTRIX. (2005). Prescribing information. GlaxoSmithKline Biologicals, Rixensart, Belgium.
6. Broder, K., & Mijalski, C. (2005, March). A big whoop: Current challenges and new directions for pertussis in the United States. Paper presented at the 39th National Immunization Conference, Washington, DC.
7. Caro, J. J., Getsios, D., El-Hadi, W., Payne, K., O'Brien, J.A., & Tan, T., for the Global Pertussis Initiative. (2003, September). The economic impact of vaccinating adolescents for pertussis (poster G-1644). Poster presented at the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL.
8. Cattaneo L.A., Reed G.W., Haase D.H., Wills M.J., and Edwards K.M. The seroepidemiology of Bordetella pertussis infections. A study of persons ages 1-65 years. Journal of Infectious Diseases 173 (1996) 1256-1259
9. Centers for Disease Control and Prevention. Notifiable diseases/deaths in selected cities weekly information. MMWR Morbidity and Mortality Weekly Report 53 (2005) 1213-1221
10. Centers for Disease Control and Prevention. Pertussis. In: Atkinson W., Hamborsky J., and Wolfe C. (Eds). Epidemiology and prevention of vaccine-preventable diseases (2005), Public Health Foundation, Washington, DC 75-88
11. Centers for Disease Control and Prevention. Summary of notifiable diseases-United States, 2003. MMWR Morbidity and Mortality Weekly Report 52 (2005) 1-85
12. Centers for Disease Control and Prevention. Summary of notifiable diseases-United States, 2002. MMWR Morbidity and Mortality Weekly Report 51 (2004) 1-84
13. Centers for Disease Control and Prevention. Vaccination coverage among children entering school-United States, 2003-2004 school year. MMWR Morbidity and Mortality Weekly Report 53 (2004) 1041-1044
14. Centers for Disease Control and Prevention. Youth risk behavior surveillance-United States, 2003. MMWR Morbidity and Mortality Weekly Report 53 SS-2 (2004) 1-100
15. Centers for Disease Control and Prevention. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Morbidity and Mortality Weekly Report 51 (2002) 1-36
16. Centers for Disease Control and Prevention. Pertussis-United States, 1997-2000. MMWR Morbidity and Mortality Weekly Report 51 (2002) 73-76
17. Centers for Disease Control and Prevention. Summary of notifiable diseases-United States, 1999. MMWR Morbidity and Mortality Weekly Report 48 (2001) 1-104
18. Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. MMWR Morbidity and Mortality Weekly Report 46 (1997) 1-55
19. Centers for Disease Control and Prevention. Pertussis outbreak-Vermont, 1996. MMWR Morbidity and Mortality Weekly Report 46 (1997) 822-826
20. Centers for Disease Control and Prevention. Status report on the Childhood Immunization Initiative. National, state, and urban area vaccination coverage levels among children aged 19-35 months-United States, 1996. MMWR Morbidity and Mortality Weekly Report 46 (1997) 657-664
21. Centers for Disease Control and Prevention. Summary of notifiable diseases-United States, 1996. MMWR Morbidity and Mortality Weekly Report 45 (1997) 1-87
22. Centers for Disease Control and Prevention. Summary of notifiable diseases-United States, 1993. MMWR Morbidity and Mortality Weekly Report 42 (1994) 1-73
23. Cherry J.D. Epidemiological, clinical, and laboratory aspects of pertussis in adults. Clinical Infectious Disease 28 (1999) S112-S117
24. Daum, R. S., Marshall, G., Walter, E., & Bologa, M. (2004). Immunogenicity of tetanus-diphtheria-acellular pertussis (TdaP) vaccine in adolescents. Abstract presented at the American Academy of Pediatrics National Conference and Exhibition, San Francisco, CA.
25. Davis J.P. Clinical and economic effects of pertussis outbreaks. Pediatric Infectious Disease Journal 24 (2005) S109-S116
26. De Serres G., Shadmani R., Duval B., Boulianne N., Déry P., Fradet M.D., et al. Morbidity of pertussis in adolescents and adults. Journal of Infectious Disease 182 (2000) 174-179
27. Deen J.L., Mink C.M., Cherry J.D., Christenson P.D., Pineda E.F., Lewis K., et al. Household contact study of Bordetella pertussis infections. Clinical Infectious Disease 21 (1995) 1211-1219
28. Dey A.N., and Bloom B. Summary health statistics for the US children. National Health Interview Survey, 2003. Vital Health Statistics 10 (2005) 1-78
29. Dworkin M.S. Adults are whooping, but are internists listening?. Annals Internal Medicine 142 (2005) 832-835
30. Forsyth K.D., Campins-Marti M., Caro J., Cherry J.D., Greenberg D., Guiso N., et al. New pertussis vaccination strategies beyond infancy. Recommendations by the Global Pertussis Initiative. Clinical Infectious Disease 39 (2004) 1802-1809
31. Foundation for Accountability, and The Robert Wood Johnson Foundation. A portrait of adolescents in America, 2001 (2001), The Foundation for Accountability, Portland, OR
32. ™ Vaccine Study Group. Reduced antigen content tetanus-diphtheria-acellular pertussis (Tdap) vaccine is immunogenic and safe in adolescents. Results of a randomized trial (2004) Abstract presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC.
33. Güris D., Strebel P.M., Bardenheier B., Brennan M., Tachdjian R., Finch E., et al. Changing epidemiology of pertussis in the United States. Increasing reported incidence among adolescents and adults, 1990-1996. Clinical Infectious Disease 28 (1999) 1230-1237
34. Halperin S.A. Canadian experience with implementation of an acellular pertussis vaccine booster-dose program in adolescents. Implications for the United States. Pediatric Infectious Disease Journal 24 (2005) S141-S146
35. Halperin S.A., Smith B., Russell M., Scheifele D., Mills E., Hasselback P., et al. Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatric Infectious Disease Journal 19 (2000) 276-283
36. Hewlett E.L., and Edwards K.M. Pertussis-not just for kids. New England Journal of Medicine 352 (2005) 1215-1222
37. Institute of Medicine. Vaccines for the 21st century. A tool for decision-making (2000), National Academy Press, Washington, DC
38. Jenkinson D. Duration of effectiveness of pertussis vaccine. Evidence from a 10 year community study. British Medical Journal 296 (1988) 612-614
39. Kenyon T.A., Izurieta H., Shulman S.T., Rosenfeld E., Miller M., Daum R., et al. Large outbreak of pertussis among young children in Chicago, 1993. Investigation of potential contributing factors and estimation of vaccine effectiveness. Pediatric Infectious Disease Journal 15 (1996) 655-661
40. Khetsuriani N., Bisgard K., Prevots D.R., Brennan M., Wharton M., Pandya S., et al. Pertussis outbreak in an elementary school with high vaccination coverage. Pediatric Infectious Disease Journal 20 (2001) 1108-1112
41. Le T., Cherry J.D., Chang S.J., Knoll M.D., Lee M.L., Barenkamp S., et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine. The APERT study. Journal of Infectious Disease 190 (2004) 535-544
42. Lee G.M., Lett S., Schauer S., LeBaron C., Murphy T.V., Rusinak D., et al. Societal costs and morbidity of pertussis in adolescents and adults. Clinical Infectious Disease 39 (2004) 1572-1580
43. Minh N.N.T., He Q., Ramalho A., Kaufhold A., Viljanen M.K., Arvilommi H., et al. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics 104 (1999) e70-e76
44. National Committee for Quality Assurance. Adolescent immunization status. State of health care quality report (2003). http://www.ncqa.org/sohc2003/adolescent_immunization_status.htm Retrieved April 12, 2005, from http://www.ncqa.org/sohc2003/adolescent_immunization_status.htm.
45. Ozer E.M., Park M.J., Paul T., Brindis C.D., and Irwin Jr. C.E. America's adolescents. Are they healthy? (2003), National Adolescent Health Information Center, San Francisco, CA
46. Pichichero M.E., and Treanor J. Economic impact of pertussis. Archives of Pediatrics & Adolescent Medicine 151 (1997) 35-40
47. Pichichero, M. E., Blatter, M. M., Kennedy, W. A., Hendrick, J., Descamps, D., & Friedland, L. R. (2006). Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatric Infectious Disease Journal, 117, in press.
48. Pichichero M.E., Rennels M.B., Edwards K.M., Blatter M.M., Marshall G.S., Bologa M., et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA 293 (2005) 3003-3011
49. Purdy K.W., Hay J.W., Botteman M.F., and Ward J.I. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults. A cost-benefit analysis. Clinical Infectious Disease 39 (2004) 20-28
50. Rickert D., Deladisma A., Yusuf H., Averhoff F., Brink E., and Shih S. Adolescent immunizations. Are we ready for a new wave?. American Journal Preventive Medicine 26 (2004) 22-28
51. Schaffer S.J., Humiston S.G., Shone L.P., Averhoff F.M., and Szilagyi P.G. Adolescent immunization practices. A national survey of US physicians. Archives Pediatrics Adolescent Medicine 155 (2001) 566-571
52. Sotir, M. J., Cappazzo, D. L., Schmidt, C. E., Warshauer, D. M., Zastrow, J. A., Monson, T. A., et al. (2005, March). A resource and labor intensive county-wide outbreak of pertussis, Wisconsin, 2003: High impact on the adolescent population. Abstract presented at the 39th National Immunization Conference, Washington, DC.
53. Strebel P., Nordin J., Edwards K., Hunt J., Besser J., Burns S., et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996. Journal of Infectious Disease 183 (2001) 1353-1359
54. US Census Bureau. Census 2000 briefs: Hispanic or Latino origin population; white alone not-Hispanic or Latino origin population; and population other than white alone not-Hispanic or Latino origin, by age and sex for the United States: 2000 (2000). http://www.census.gov/population/cen2000/phc-t08/tab08.pdf Retrieved April 12, 2005, from http://www.census.gov/population/cen2000/phc-t08/tab08.pdf.
55. US Department of Health and Human Services. Healthy People 2010. Understanding and improving health. 2nd ed. (2000), US Government Printing Office, Washington, DC
56. Van Damme P., and Burgess M. Immunogenicity of a combined diphtheria-tetanus-acellular pertussis vaccine in adults. Vaccine 22 (2004) 305-308
57. Van der Wielen M., Van Damme P., Joossens E., Francois G., Meurice F., and Ramalho A. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine 18 (2000) 2075-2082
58. Wirsing von König C.H., Postels-Multani S., Bock H.L., and Schmitt H.J. Pertussis in adults. Frequency of transmission after household exposure. Lancet 346 (1995) 1326-1329
59. Yaari E., Yafe-Zimerman Y., Schwartz S.B., Slater P.E., Shvartzman P., Andoren N., et al. Clinical manifestations of Bordetella pertussis infection in immunized children and young adults. Chest 115 (1999) 1254-1258
60. Yih W.K., Lett S.M., des Vignes F.N., Garrison K.M., Sipe P.L., and Marchant C.D. The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989-1998. Journal of Infectious Disease 182 (2000) 1409-1416
61. Ziv A., Boulet J.R., and Slap G.B. Utilization of physician offices by adolescents in the United States. Pediatrics 104 (1999) 35-42